This compound is a synthetic derivative of 6-methylsulfinyl-hexane isothiocyanate, which was initially produced by Wasabia; it is an analog of sulforaphane. This isothiocyanate (ITC) exhibits anticancer chemotherapeutic, anti-inflammatory, antioxidative, and neuroprotective activities. This compound inhibits SOX2 signaling, induces G2/M phase cell cycle arrest, and suppresses cell viability in pancreatic cancer cells. This compound also decreases tumor volume and weight in animal models of breast cancer. Additionally, this ITC inhibits expression of COX-2, iNOS, and inflammatory cytokines in macrophages. In striatal cultures, this compound activates Nrf2 and increases levels of heme oxygenase 1 (HO-1), suppressing oxidative stress. This isothiocyanate also inhibits GSK-3β.